UCSF

ZINC01530689

Substance Information

In ZINC since Heavy atoms Benign functionality
October 28th, 2005 28 Yes

Other Names:

(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphe

(Z)-2-(p-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine citrate (1:1); Ethanamine, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl, (Z)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1); trans-1-(p-beta-Dimethylaminoethoxyphenyl)-1,2-diphenylbut-1

ifen(e)

10540-29-1; C07108; Tamoxifen

10540-29-1; CPD001491671; SAM002703133; Tamoxifen

10540-29-1; D08559; Tamoplex (TN); Tamoxifen (INN); Tamoxifen (TN)

5-[(2R)-2-[[2-(2-Ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide hydrochloride

54965-24-1; D00966; Nolvadex (TN); Tamoxifen citrate (JP16/USP)

54965-24-1; Prestwick_458; Tamoxifen citrate

Apo-Tamox

Apo-Tamox; Crisafeno; Diemon

BRD-K93754473-001-02-9

BRD-K93754473-048-05-3

CHEBI:41767; CHEBI:9396

Citofen

CPD-4541; tamoxifen

CPD001491671; SAM002703133; Tamoxifen

Crisafeno

Diemon

DIPHENYLBUTENYLPHENOXYETHYLDIMETHYLAMINEHYDROXYPROPANETRICARBOXYLAT

DNC001393

Ethanamine, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, (Z)-, 2-hydroxy-1,2,3-propanetricarboxylate; Ethylamine, 2-(p-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, citrate (Z)-; I.C.I. 46474 citrate; LS-68202; N,N-Dimethyl-2-(p-(1,2-diphenyl-1-

ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt)

FDA)

Gen-Tamoxifen

ICI-46474

INN)

INN); Tamoxifen citrate (FDA

INN); Tamoxifen Citrate (JAN

Istubal

Istubol

JAN

Kessar

Kessar; Nolvadex; Tamox; Tamoxan; Tamoxene; Tamoxin

MFCD00010454

MFCD00058321

Noltam

Nolvadex

Nolvadex-D

Nourytam

Novo-Tamoxifen

Oncomox

PMS-Tamoxifen

QA-3523

Retaxim

Soltamox

Sulphameth oxazole

Tamizam

Tamofen

Tamone

Tamoxasta

Tamoxen

Tamoxifen

Tamoxifen (BAN

Tamoxifen Citrate

Tamoxifen Citrate (FDA

Tamoxifen Citrate (Nolvadex)

Tamoxifen citrate, 98%

Tamoxifen Citrate;Tamoxifene [INN-French];Tamoxifeno [INN-Spanish];Tamoxifenum [INN-Latin];Trans-Tamoxifen

tamoxifen drug standard solution

tamoxifen; tamoxifene; tamoxifeno; tamoxifenum

Tamoxifene [INN-French]

Tamoxifeno [INN-Spanish]

Tamoxifenum [INN-Latin]

Tamoxifenum [INN-Latin];Tamoxifeno [INN-Spanish];Tamoxifene [INN-French];Trans-Tamoxifen;Tamoxifen Citrate

Tamsulosine hydrochloride

trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine

Trans-Tamoxifen

USAN

USP

USP)

USP); Tamoxifen (BAN

Valodex

Zemide

Zynoplex

{2-[4-(1,2-Diphenyl-1-buten-1-yl)phenoxy]ethyl}dim ethylamine 2-hydroxy-1,2,3-propanetricarboxylate (

{2-[4-(1,2-Diphenyl-1-buten-1-yl)phenoxy]ethyl}dimethylamine 2-hydroxy-1,2,3-propanetricarboxylate (

{2-[4-(1,2-diphenylbut-1-en-1-yl)phenoxy]ethyl}dimethylamine

Download: MOL2 SDF SMILES Flexibase

Annotations

Vendors

Physical Representations

Type pH range xlogP Des A‑Pol Apolar desolvation (kcal/mol) Des Pol Polar desolvation (kcal/mol) H Don H-bond donors H Acc H-bond acceptors Chg Net charge tPSA (Ų) MWT Molecular weight (g/mol) RB Rotatable bonds DL
Ref Reference (pH 7) 6.06 15.81 -35.9 1 2 1 14 372.532 8
Hi High (pH 8-9.5) 6.06 13.36 -4.97 0 2 0 12 371.524 8

Vendor Notes

Note Type Comments Provided By
ALOGPS_SOLUBILITY 1.02e-03 g/l DrugBank-approved
Mp [°C] 140 - 144 Acros Organics
Therapy Anti-estrogen; relatively selective protein kinase C inhibitor SMDC Iconix
Indications antineoplastic KeyOrganics Bioactives
Indications breast cancer KeyOrganics Bioactives
UniProt Database Links COM1_HUMAN; CUED2_HUMAN; CUZD1_RAT; ESR1_HUMAN; ESR2_HUMAN; F102A_HUMAN; FOXL2_BOVIN; FOXL2_CAPHI; FOXL2_ELLLU; FOXL2_HUMAN; FOXL2_MOUSE; FOXL2_PIG; FOXL2_RABIT; NLTP_HUMAN; NUMBL_MOUSE; NUMB_MOUSE ChEBI
Patent Database Links EP0911321; EP0995748; EP1133996; EP1192945; EP1438962; EP1506775; EP1514877; EP1531181; EP1537858; EP1538164; EP1557085; EP1574499; EP1580188; EP1586323; EP1598081; EP1611879; EP1623712; EP1634607; EP1683523; EP1692936; EP1717247; EP1731142; EP1738752; EP ChEBI
Patent Database Links EP1719527; EP1728863; EP1829534; EP1834637; EP1911449; US2005042279; US2007184076; US2007196272 ChEBI
therap estrogen antagonist, antineoplastic MicroSource Spectrum
Target Estrogen/progestogen Receptor Selleck Chemicals
H phrase H302: Harmful if swallowed Acros Organics
H phrase H302: Harmful if swallowed; H350: May cause cancer Acros Organics
Warnings IRRITANT Matrix Scientific
PUBCHEM_SUBSTANCE_COMMENT NCC_SAMPLE_SUPPLIER : LightBiologicals; NCC_SUPPLIER_STRUCTURE_ID : MZ-3027; NCC_SUPPLIER_SAMPLE_COMMENTS : WHITE POWDER NIH Clinical Collection via PubChem
P phrase P201: Obtain special instructions before use Acros Organics
P phrase P201: Obtain special instructions before use; P308 + P313: IF exposed or concerned: Get medical advice/attention; P301+ P312: IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell Acros Organics
R phrase R45: May cause cancer. Acros Organics
R phrase R45: May cause cancer.; R22: Harmful if swallowed. Acros Organics
Reactome Database Links REACT_13805; REACT_6956 ChEBI
S phrase S53: Avoid exposure - obtain special instructions before use. Acros Organics
S phrase S53: Avoid exposure - obtain special instructions before use.; S45: In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). Acros Organics
PUBCHEM_SUBSTANCE_COMMENT SAMPLE_SUPPLIER: LightBiologicals; SUPPLIER_STRUCTURE_ID: MZ-3027; SUPPLIER_COMMENTS: WHITE POWDER NIH Clinical Collection via PubChem
Hazard T: Toxic Acros Organics
PUBCHEM_PATENT_ID WO2000025767A2 IBM Patent Data

Activity (Go SEA)

Clustered Target Annotations
Code Description Organism Class Affinity (nM) LE (kcal/mol/atom) Type
EBP-1-E 3-beta-hydroxysteroid-delta(8),delta(7)-isomerase (cluster #1 Of 1), Eukaryotic Eukaryotes 5 0.42 Binding ≤ 10μM
ESR1-1-E Estrogen Receptor Alpha (cluster #1 Of 5), Eukaryotic Eukaryotes 8 0.40 Binding ≤ 10μM
ESR2-1-E Estrogen Receptor Beta (cluster #1 Of 4), Eukaryotic Eukaryotes 3900 0.27 Binding ≤ 10μM
KCNH2-2-E HERG (cluster #2 Of 5), Eukaryotic Eukaryotes 1585 0.29 Binding ≤ 10μM
MDR1-1-E P-glycoprotein 1 (cluster #1 Of 3), Eukaryotic Eukaryotes 100 0.35 Binding ≤ 10μM
O77823-1-E Phosphodiesterase 4A (cluster #1 Of 1), Eukaryotic Eukaryotes 6800 0.26 Binding ≤ 10μM
PDE1A-1-E Phosphodiesterase 1A (cluster #1 Of 1), Eukaryotic Eukaryotes 6800 0.26 Binding ≤ 10μM
PDE1B-1-E Phosphodiesterase 1B (cluster #1 Of 1), Eukaryotic Eukaryotes 6750 0.26 Binding ≤ 10μM
PDE1C-1-E Phosphodiesterase 1C (cluster #1 Of 1), Eukaryotic Eukaryotes 6800 0.26 Binding ≤ 10μM
Q8AWE3-1-E Serine-threonine Protein Phosphatase 2A Regulatory Subunit (cluster #1 Of 1), Eukaryotic Eukaryotes 3400 0.27 Binding ≤ 10μM
SGMR1-1-E Sigma Opioid Receptor (cluster #1 Of 6), Eukaryotic Eukaryotes 35 0.37 Binding ≤ 10μM
ESR1-1-E Estrogen Receptor Alpha (cluster #1 Of 3), Eukaryotic Eukaryotes 904 0.30 Functional ≤ 10μM
ESR2-1-E Estrogen Receptor Beta (cluster #1 Of 2), Eukaryotic Eukaryotes 904 0.30 Functional ≤ 10μM
CP2B6-2-E Cytochrome P450 2B6 (cluster #2 Of 4), Eukaryotic Eukaryotes 900 0.30 ADME/T ≤ 10μM
CP3A4-2-E Cytochrome P450 3A4 (cluster #2 Of 4), Eukaryotic Eukaryotes 200 0.33 ADME/T ≤ 10μM
ERG2-2-F C-8 Sterol Isomerase (cluster #2 Of 2), Fungal Fungi 1500 0.29 Binding ≤ 10μM
Z100267-1-O Anti-estrogen Binding Site (AEBS) (cluster #1 Of 1), Other Other 12 0.40 Binding ≤ 10μM
Z50425-11-O Plasmodium Falciparum (cluster #11 Of 22), Other Other 7943 0.26 Functional ≤ 10μM
Z80132-2-O EL4 (Thymoma Cells) (cluster #2 Of 2), Other Other 535 0.31 Functional ≤ 10μM
Z80224-1-O MCF7 (Breast Carcinoma Cells) (cluster #1 Of 14), Other Other 904 0.30 Functional ≤ 10μM
Z80227-1-O MCF7-ADR (Breast Carcinoma Cells) (cluster #1 Of 2), Other Other 2000 0.28 Functional ≤ 10μM
Z80231-2-O MCF7S (Breast Carcinoma Cells) (cluster #2 Of 2), Other Other 7200 0.26 Functional ≤ 10μM
Z80296-1-O MVLN (cluster #1 Of 1), Other Other 300 0.33 Functional ≤ 10μM
Z80712-2-O T47D (Breast Carcinoma Cells) (cluster #2 Of 7), Other Other 1000 0.30 Functional ≤ 10μM
Z81068-1-O Ishikawa (Uterine Carcinoma Cells) (cluster #1 Of 1), Other Other 420 0.32 Functional ≤ 10μM
Z81245-1-O MDA-MB-435 (Breast Carcinoma Cells) (cluster #1 Of 6), Other Other 50 0.37 Functional ≤ 10μM
Z81252-1-O MDA-MB-231 (Breast Adenocarcinoma Cells) (cluster #1 Of 11), Other Other 9860 0.25 Functional ≤ 10μM
Z80936-1-O HEK293 (Embryonic Kidney Fibroblasts) (cluster #1 Of 4), Other Other 10000 0.25 ADME/T ≤ 10μM
ChEMBL Target Annotations
Uniprot Swissprot Description Affinity (nM) LE (kcal/mol/atom) Type
EBP_HUMAN Q15125 3-beta-hydroxysteroid-delta(8),delta(7)-isomerase, Human 5 0.42 Binding ≤ 1μM
Z100267 Z100267 Anti-estrogen Binding Site (AEBS) 1 0.45 Binding ≤ 1μM
ESR1_HUMAN P03372 Estrogen Receptor Alpha, Human 100 0.35 Binding ≤ 1μM
ESR2_HUMAN Q92731 Estrogen Receptor Beta, Human 11.9 0.40 Binding ≤ 1μM
MDR1_HUMAN P08183 P-glycoprotein 1, Human 100 0.35 Binding ≤ 1μM
SGMR1_HUMAN Q99720 Sigma Opioid Receptor, Human 35 0.37 Binding ≤ 1μM
EBP_HUMAN Q15125 3-beta-hydroxysteroid-delta(8),delta(7)-isomerase, Human 5 0.42 Binding ≤ 10μM
Z100267 Z100267 Anti-estrogen Binding Site (AEBS) 1 0.45 Binding ≤ 10μM
ERG2_YEAST P32352 C-8 Sterol Isomerase, Yeast 1500 0.29 Binding ≤ 10μM
ESR1_HUMAN P03372 Estrogen Receptor Alpha, Human 100 0.35 Binding ≤ 10μM
ESR2_HUMAN Q92731 Estrogen Receptor Beta, Human 11.9 0.40 Binding ≤ 10μM
KCNH2_HUMAN Q12809 HERG, Human 1584.89319 0.29 Binding ≤ 10μM
MDR1_HUMAN P08183 P-glycoprotein 1, Human 100 0.35 Binding ≤ 10μM
PDE1A_HUMAN P54750 Phosphodiesterase 1A, Human 6750 0.26 Binding ≤ 10μM
PDE1B_RAT Q01066 Phosphodiesterase 1B, Rat 6750 0.26 Binding ≤ 10μM
PDE1B_HUMAN Q01064 Phosphodiesterase 1B, Human 6750 0.26 Binding ≤ 10μM
PDE1C_HUMAN Q14123 Phosphodiesterase 1C, Human 6750 0.26 Binding ≤ 10μM
O77823_PIG O77823 Phosphodiesterase 4A, Pig 6800 0.26 Binding ≤ 10μM
Q8AWE3_CHICK Q8AWE3 Serine-threonine Protein Phosphatase 2A Regulatory Subunit, Chick 3400 0.27 Binding ≤ 10μM
SGMR1_HUMAN Q99720 Sigma Opioid Receptor, Human 35 0.37 Binding ≤ 10μM
Z80132 Z80132 EL4 (Thymoma Cells) 535 0.31 Functional ≤ 10μM
ESR1_HUMAN P03372 Estrogen Receptor Alpha, Human 2540 0.28 Functional ≤ 10μM
ESR2_HUMAN Q92731 Estrogen Receptor Beta, Human 1660 0.29 Functional ≤ 10μM
Z81068 Z81068 Ishikawa (Uterine Carcinoma Cells) 170 0.34 Functional ≤ 10μM
Z80224 Z80224 MCF7 (Breast Carcinoma Cells) 0.11 0.50 Functional ≤ 10μM
Z80227 Z80227 MCF7-ADR (Breast Carcinoma Cells) 2000 0.28 Functional ≤ 10μM
Z80231 Z80231 MCF7S (Breast Carcinoma Cells) 7200 0.26 Functional ≤ 10μM
Z81252 Z81252 MDA-MB-231 (Breast Adenocarcinoma Cells) 10000 0.25 Functional ≤ 10μM
Z81245 Z81245 MDA-MB-435 (Breast Carcinoma Cells) 50 0.37 Functional ≤ 10μM
Z80296 Z80296 MVLN 300 0.33 Functional ≤ 10μM
Z50425 Z50425 Plasmodium Falciparum 7943.28235 0.25 Functional ≤ 10μM
Z80712 Z80712 T47D (Breast Carcinoma Cells) 1000 0.30 Functional ≤ 10μM
CP2B6_HUMAN P20813 Cytochrome P450 2B6, Human 900 0.30 ADME/T ≤ 10μM
CP3A4_HUMAN P08684 Cytochrome P450 3A4, Human 200 0.33 ADME/T ≤ 10μM
Z80936 Z80936 HEK293 (Embryonic Kidney Fibroblasts) 10000 0.25 ADME/T ≤ 10μM

Direct Reactome Annotations (via ChEBI)

Description Species
FMO oxidizes nucleophiles
Glucuronidation

Reactome Annotations from Targets (via Uniprot)

Description Species
Abacavir transmembrane transport
ABC-family proteins mediated transport
Aflatoxin activation and detoxification
Cam-PDE 1 activation
cGMP effects
Cholesterol biosynthesis
CYP2E1 reactions
DARPP-32 events
Fatty acids
G alpha (s) signalling events
Nuclear Receptor transcription pathway
Nuclear signaling by ERBB4
Voltage gated Potassium channels
Xenobiotics

Analogs ( Draw Identity 99% 90% 80% 70% )